• Blog
  • Equity Research
    • Sector Rotation
    • Stock Wise Rotation
    • Case Study
    • Shareholding
    • Blockbuster Quarterly Result
  • Market Weekly
  • IPO Analysis
  • About
What's New!

Ather Energy Limited | IPO Analysis

28 April 2025

Laxmi Dental Limited | IPO Analysis

13 January 2025

Quadrant Future Tek Limited | IPO Analysis

7 January 2025
Facebook Instagram YouTube LinkedIn
Facebook Instagram YouTube LinkedIn
InwealfoneyInwealfoney
  • Blog
  • Equity Research
    • Sector Rotation
    • Stock Wise Rotation
    • Case Study
    • Shareholding
    • Blockbuster Quarterly Result
  • Market Weekly
  • IPO Analysis
  • About
InwealfoneyInwealfoney
Home»IPO Analysis»Akums Drugs and Pharmaceuticals Limited | IPO Analysis
IPO Analysis

Akums Drugs and Pharmaceuticals Limited | IPO Analysis

Vicky NagarBy Vicky Nagar30 July 2024Updated:30 July 2024No Comments3 Mins Read
Share
Facebook Twitter LinkedIn WhatsApp

Company Overview

Akums Drugs and Pharmaceuticals Limited, established in 2004, has become a leading entity in the pharmaceutical industry. As a contract development and manufacturing organization (CDMO), it serves markets both in India and internationally.

Key Services

The company provides a wide range of services, including:

  • Comprehensive solutions for product development and manufacturing
  • Research and development (R&D) of formulations
  • Preparation and submission of regulatory dossiers for Indian and international markets
  • Various testing services
  • Manufacturing and sales of branded drugs and active pharmaceutical ingredients (APIs)

Manufacturing Capabilities

Akums boasts impressive manufacturing capabilities with:

  • Ten manufacturing facilities with a combined annual production capacity of 49.21 billion units (as of September 30, 2023)
  • Production of various dosage forms such as tablets, capsules, and liquid medicines
  • Over 4,025 commercialized formulations across more than 60 dosage forms

Regulatory Accreditations

The company has received several significant regulatory accreditations, including:

  • European Good Manufacturing Practice (EU-GMP)
  • World Health Organization Good Manufacturing Practice (WHO-GMP)
  • United States National Sanitation Foundation (US NSF)

Objectives of the IPO

The proceeds from the IPO are planned to be utilized for:

  • Repaying or prepaying debt for the company and its subsidiaries
  • Funding additional working capital requirements
  • Supporting inorganic growth through acquisitions
  • General corporate purposes

Summary of Financial Information:

Here's the updated code with the new data: ```html
Period Ended 31-Mar-24 31-Mar-23 31-Mar-22
Assets 3,516.37 3,266.53 3,069.05
Revenue 4,212.21 3,700.93 3,694.52
Profit After Tax 0.79 97.82 -250.87
Net Worth 709.5 717.19 621.98
Reserves and Surplus 861.01 868.7 787.79
Total Borrowing 491.56 536.97 357.95
Amount in Rs. Crore

Comparison with Listed Peers:

Company Name P/E P/B RoE (%)
Akums Drugs & Pharmaceuticals Ltd 30 14 17
Divi's Laboratories Ltd 78 9 12
Suven Pharmaceuticals Ltd 80 12 16
Gland Pharma Ltd 43 4 10
Torrent Pharmaceuticals Ltd 61 15 25
Alkem Laboratories Ltd 35 6 11
Eris Lifesciences Ltd 37 6 18
JB Chemicals & Pharmaceuticals Ltd 53 10 19
Mankind Pharma Ltd 44 9 23
Innova Captab Ltd 38 4 28
As on March 30, 2024

Key details of the IPO:

IPO Dates: 30 July to 1 Aug, 2024

Price Band: Rs. 646 to Rs. 679 per share

Lot Size: 22 shares

Listing Date: 6 Aug, 2024

Total Issue Size: Rs. 1,856.74 Cr. (Fresh Issue = Rs. 680 Cr. )

Retail Quota: 10%

GMP: Rs. 180 (Only for information purposes.)

Allotment Link

Note: For additional information & risk factors please refer to the Red Herring Prospectus

Join our WhatsApp Group for Trading/Investment ideas & Market Updates 👇

Click me

Disclaimer: We are not SEBI registered. All the views are personal and only for educational purposes. Do your due diligence before making any trading or investing decisions. The data provided in this blog post is for illustrative purposes only and does not constitute financial advice. Always consult with a qualified financial advisor before making investment decisions.

IPO Analysis IPO GMP IPO Summary IPO Updates Stock Market IPOs Upcoming IPOs
Share. Facebook Twitter LinkedIn WhatsApp
Previous ArticleUnion Budget 2024: Highlights
Next Article Ceigall India Limited | IPO Analysis
Vicky Nagar
  • Website

Vicky Nagar is an equity trader with 5+ years of experience in trading and investing. He has expertise in equity valuation, sectoral analysis, index analysis, and in identifying the market trends. He is a NISM Certified Research Analyst. Formerly a relationship manager at Kotak Mahindra Bank Limited in the Agri-Business Group, he also has teaching experience at KS School of Business Management, Gujarat University, and as an Academic Associate at IRMA (Institute of Rural Management Anand). He holds a BBA (Gold Medalist) and an MBA (Gold Medalist) in Marketing.

Related Posts

28 April 2025

Ather Energy Limited | IPO Analysis

28 April 2025By Vicky Nagar
Read More
13 January 2025

Laxmi Dental Limited | IPO Analysis

13 January 2025By Vicky Nagar
Read More
7 January 2025

Quadrant Future Tek Limited | IPO Analysis

7 January 2025By Vicky Nagar
Read More

Leave A Reply Cancel Reply

Top Posts
© 2025 Inwealfoney. All rights reserved..

Type above and press Enter to search. Press Esc to cancel.